Wet Age Related Macular Degeneration (AMD) Market Report

USA Wet Age Related Macular Degeneration (AMD) Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Dec 11, 2022
  • PAGES：156
  • REPORT CODE：GMM1454118
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

    This report offers an overview of the market trends, drivers, and barriers with respect to the USA Wet Age Related Macular Degeneration (AMD) market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Wet Age Related Macular Degeneration (AMD) market. Detailed analysis of key players, along with key growth strategies adopted by Wet Age Related Macular Degeneration (AMD) industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Alimera Sciences Inc

    • Neurotech Pharmaceuticals Inc

    • Bayer AG

    • Ophthotech Corporation

    • Gilead Sciences Inc

    • F Hoffmann-La Roche Ltd (Roche)

    • Novartis AG

    • Kubota Pharmaceutical Holdings Co Ltd

    • Regeneron Pharmaceuticals Inc

    By Type:

    • Lucentis

    • Eylea

    • Avastin

    By End-User:

    • Hospitals and Clinics

    • Research and Academic Institute

    By Region:

    • West USA

    • South USA

    • Middle West USA

    • Northeast USA

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Wet Age Related Macular Degeneration (AMD) Market

    • 1.3 Market Segment by Type

      • 1.3.1 USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Lucentis from 2016 to 2027

      • 1.3.2 USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Eylea from 2016 to 2027

      • 1.3.3 USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Avastin from 2016 to 2027

    • 1.4 Market Segment by Application

      • 1.4.1 USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Hospitals and Clinics from 2016 to 2027

      • 1.4.2 USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Research and Academic Institute from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 West USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 South USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Wet Age Related Macular Degeneration (AMD) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Wet Age Related Macular Degeneration (AMD) by Major Types

      • 3.4.1 Market Size and Growth Rate of Lucentis

      • 3.4.2 Market Size and Growth Rate of Eylea

      • 3.4.3 Market Size and Growth Rate of Avastin

    4 Segmentation of Wet Age Related Macular Degeneration (AMD) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Wet Age Related Macular Degeneration (AMD) by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Wet Age Related Macular Degeneration (AMD) in Hospitals and Clinics

      • 4.4.2 Market Size and Growth Rate of Wet Age Related Macular Degeneration (AMD) in Research and Academic Institute

    5 Market Analysis by Regions

    • 5.1 USA Wet Age Related Macular Degeneration (AMD) Production Analysis by Regions

    • 5.2 USA Wet Age Related Macular Degeneration (AMD) Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on USA Economy

    6 West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis

    • 6.1 West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major Types

    • 6.2 West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major End-Users

    7 South USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis

    • 7.1 South USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major Types

    • 7.2 South USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major End-Users

    8 Middle West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis

    • 8.1 Middle West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major Types

    • 8.2 Middle West USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major End-Users

    9 Northeast USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis

    • 9.1 Northeast USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major Types

    • 9.2 Northeast USA Wet Age Related Macular Degeneration (AMD) Landscape Analysis by Major End-Users

    10 Major Players Profiles

      • 10.1 Alimera Sciences Inc

        • 10.1.1 Alimera Sciences Inc Company Profile and Recent Development

        • 10.1.2 Market Performance

        • 10.1.3 Product and Service Introduction

      • 10.2 Neurotech Pharmaceuticals Inc

        • 10.2.1 Neurotech Pharmaceuticals Inc Company Profile and Recent Development

        • 10.2.2 Market Performance

        • 10.2.3 Product and Service Introduction

      • 10.3 Bayer AG

        • 10.3.1 Bayer AG Company Profile and Recent Development

        • 10.3.2 Market Performance

        • 10.3.3 Product and Service Introduction

      • 10.4 Ophthotech Corporation

        • 10.4.1 Ophthotech Corporation Company Profile and Recent Development

        • 10.4.2 Market Performance

        • 10.4.3 Product and Service Introduction

      • 10.5 Gilead Sciences Inc

        • 10.5.1 Gilead Sciences Inc Company Profile and Recent Development

        • 10.5.2 Market Performance

        • 10.5.3 Product and Service Introduction

      • 10.6 F Hoffmann-La Roche Ltd (Roche)

        • 10.6.1 F Hoffmann-La Roche Ltd (Roche) Company Profile and Recent Development

        • 10.6.2 Market Performance

        • 10.6.3 Product and Service Introduction

      • 10.7 Novartis AG

        • 10.7.1 Novartis AG Company Profile and Recent Development

        • 10.7.2 Market Performance

        • 10.7.3 Product and Service Introduction

      • 10.8 Kubota Pharmaceutical Holdings Co Ltd

        • 10.8.1 Kubota Pharmaceutical Holdings Co Ltd Company Profile and Recent Development

        • 10.8.2 Market Performance

        • 10.8.3 Product and Service Introduction

      • 10.9 Regeneron Pharmaceuticals Inc

        • 10.9.1 Regeneron Pharmaceuticals Inc Company Profile and Recent Development

        • 10.9.2 Market Performance

        • 10.9.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Lucentis from 2016 to 2027

    • Figure USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Eylea from 2016 to 2027

    • Figure USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Avastin from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2020

    • Figure Market Share by Type in 2027

    • Figure USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Hospitals and Clinics from 2016 to 2027

    • Figure USA Wet Age Related Macular Degeneration (AMD) Market Size and Growth Rate of Research and Academic Institute from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2020

    • Figure Market Share by End-User in 2027

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Wet Age Related Macular Degeneration (AMD) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2019

    • Figure Market Share of TOP 5 Players in 2019

    • Figure Market Share of TOP 6 Players from 2016 to 2020

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Distribution Map of USA

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Wet Age Related Macular Degeneration (AMD)

    • Figure Development Trends of Different Types

    • Table Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Wet Age Related Macular Degeneration (AMD) by Different Types from 2016 to 2027

    • Table Consumption Share of Wet Age Related Macular Degeneration (AMD) by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Lucentis

    • Figure Market Size and Growth Rate of Eylea

    • Figure Market Size and Growth Rate of Avastin

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Wet Age Related Macular Degeneration (AMD) by Different End-Users from 2016 to 2027

    • Table Consumption Share of Wet Age Related Macular Degeneration (AMD) by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospitals and Clinics

    • Figure Market Size and Growth Rate of Research and Academic Institute

    • Table USA Wet Age Related Macular Degeneration (AMD) Production by Regions

    • Table USA Wet Age Related Macular Degeneration (AMD) Production Share by Regions

    • Figure USA Wet Age Related Macular Degeneration (AMD) Production Share by Regions in 2016

    • Figure USA Wet Age Related Macular Degeneration (AMD) Production Share by Regions in 2021

    • Figure USA Wet Age Related Macular Degeneration (AMD) Production Share by Regions in 2027

    • Table USA Wet Age Related Macular Degeneration (AMD) Consumption by Regions

    • Table USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Regions

    • Figure USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Regions in 2016

    • Figure USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Regions in 2021

    • Figure USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Regions in 2027

    • Table West USA Wet Age Related Macular Degeneration (AMD) Consumption by Types from 2016 to 2027

    • Table West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types from 2016 to 2027

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2016

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2021

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2027

    • Table West USA Wet Age Related Macular Degeneration (AMD) Consumption by End-Users from 2016 to 2027

    • Table West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users from 2016 to 2027

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2016

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2021

    • Figure West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2027

    • Table South USA Wet Age Related Macular Degeneration (AMD) Consumption by Types from 2016 to 2027

    • Table South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types from 2016 to 2027

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2016

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2021

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2027

    • Table South USA Wet Age Related Macular Degeneration (AMD) Consumption by End-Users from 2016 to 2027

    • Table South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users from 2016 to 2027

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2016

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2021

    • Figure South USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2027

    • Table Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption by Types from 2016 to 2027

    • Table Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types from 2016 to 2027

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2016

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2021

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2027

    • Table Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption by End-Users from 2016 to 2027

    • Table Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users from 2016 to 2027

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2016

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2021

    • Figure Middle West USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2027

    • Table Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption by Types from 2016 to 2027

    • Table Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types from 2016 to 2027

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2016

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2021

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by Types in 2027

    • Table Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption by End-Users from 2016 to 2027

    • Table Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2016

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2021

    • Figure Northeast USA Wet Age Related Macular Degeneration (AMD) Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Alimera Sciences Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alimera Sciences Inc

    • Figure Sales and Growth Rate Analysis of Alimera Sciences Inc

    • Figure Revenue and Market Share Analysis of Alimera Sciences Inc

    • Table Product and Service Introduction of Alimera Sciences Inc

    • Table Company Profile and Development Status of Neurotech Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Neurotech Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Neurotech Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Neurotech Pharmaceuticals Inc

    • Table Product and Service Introduction of Neurotech Pharmaceuticals Inc

    • Table Company Profile and Development Status of Bayer AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer AG

    • Figure Sales and Growth Rate Analysis of Bayer AG

    • Figure Revenue and Market Share Analysis of Bayer AG

    • Table Product and Service Introduction of Bayer AG

    • Table Company Profile and Development Status of Ophthotech Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ophthotech Corporation

    • Figure Sales and Growth Rate Analysis of Ophthotech Corporation

    • Figure Revenue and Market Share Analysis of Ophthotech Corporation

    • Table Product and Service Introduction of Ophthotech Corporation

    • Table Company Profile and Development Status of Gilead Sciences Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gilead Sciences Inc

    • Figure Sales and Growth Rate Analysis of Gilead Sciences Inc

    • Figure Revenue and Market Share Analysis of Gilead Sciences Inc

    • Table Product and Service Introduction of Gilead Sciences Inc

    • Table Company Profile and Development Status of F Hoffmann-La Roche Ltd (Roche)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche Ltd (Roche)

    • Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche Ltd (Roche)

    • Figure Revenue and Market Share Analysis of F Hoffmann-La Roche Ltd (Roche)

    • Table Product and Service Introduction of F Hoffmann-La Roche Ltd (Roche)

    • Table Company Profile and Development Status of Novartis AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG

    • Figure Sales and Growth Rate Analysis of Novartis AG

    • Figure Revenue and Market Share Analysis of Novartis AG

    • Table Product and Service Introduction of Novartis AG

    • Table Company Profile and Development Status of Kubota Pharmaceutical Holdings Co Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kubota Pharmaceutical Holdings Co Ltd

    • Figure Sales and Growth Rate Analysis of Kubota Pharmaceutical Holdings Co Ltd

    • Figure Revenue and Market Share Analysis of Kubota Pharmaceutical Holdings Co Ltd

    • Table Product and Service Introduction of Kubota Pharmaceutical Holdings Co Ltd

    • Table Company Profile and Development Status of Regeneron Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Regeneron Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Regeneron Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Regeneron Pharmaceuticals Inc

    • Table Product and Service Introduction of Regeneron Pharmaceuticals Inc


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US